Roche CEO Schwan Says New Medicines Driving 'Strong Growth'

The transcript discusses the strong start to 2019, driven by newly launched medicines, leading to a raised growth outlook. It highlights the promising pipeline, including new cancer and hemophilia treatments, and addresses competition from biosimilars. The M&A strategy focuses on bolt-on acquisitions, exemplified by the Spark acquisition, enhancing gene therapy capabilities. The transcript also covers the impact of Brexit on medicine supply and the US pricing strategy, emphasizing innovation and value for patients.

What factors contributed to the strong growth reported in 2019?

What is the significance of Roche's pipeline according to Jefferies analyst Peter Welford?

How does Roche plan to address competition from biosimilars?

What is Roche's M&A strategy and how does the Spark acquisition fit into it?

What challenges does Roche face due to the ongoing Brexit situation?

How does Roche approach pricing for new medicines in the US market?

What role does innovation play in Roche's business strategy?